Navigation Links
Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
Date:6/4/2009

IRVINE, Calif., June 4 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP) the market leader in laser transmyocardial revascularization (TMR) for the treatment of chronic cardiac ischemia, announces that Dr. Naresh Trehan of New Delhi will be presenting his clinical results of combining laser TMR and stem cells to treat regions of myocardium that could not be revascularized by conventional methods. Eight patients treated with the PHOENIX System completed 1 year follow up:

  • Seven patients had concomitant coronary bypass grafting, one patient stand alone therapy.
  • There was no operative or hospital mortality. One year survival was 100%.
  • Compared to baseline, patients had NYHA Class improvement (Mean 3.5+/-0.5 to 1.33+/- 0.5, p= 0.001), and improved six minute walk test: 250+/- 112.1 seconds to 360+/-10 seconds, p=0.01.
  • MRI showed improved perfusion in the regions of myocardium treated by the PHOENIX System

The PHOENIX combination delivery system is CE Mark approved and has been used in over 50 procedures at cardiac centers outside the U.S. It is not currently FDA approved. The abstract "One Year Follow up of Combined Autologous Bone Marrow Derived Progenitor Cell Therapy and Transmyocardial Laser Revascularization for Diffuse Nongraftable Coronary Artery Disease" can be located at: http://www.ismics.org/abstracts/2009/10.html.

"These results add to the growing body of evidence that TMR has a positive impact on the intramyocardial delivery of biologics, such as stem cells. The PHOENIX System is designed to create transmural laser channels and with its three integrated injector needles, deliver the biologic into the surrounding tissue," said Richard Lanigan, President of Cardiogenesis. "These results, along with a paper recently published in the European Journal of Cardiothoracic Surgery, "Bone Marrow Laser Revascularisation for Treating Refractory Angina Due to Diffuse Coronary Heart Disease", reinforce the company's regulatory strategy of submitting an IDE for its PHOENIX System in the upcoming months."

About Cardiogenesis Corporation

Cardiogenesis is a medical device company specializing in the therapies for the treatment of chronic cardiac ischemia. The company's market leading Holmium:YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease.

For more information on the company and its products, please visit the Cardiogenesis company website at http://www.cardiogenesis.com or the direct to patient website at http://www.heartofnewlife.com.

With the exception of historical information, the statements set forth above include forward-looking statements. Any forward-looking statements in this news release related to the possible effectiveness of the company's PHOENIX delivery system or other technologies and the effect of such system or technology on the company's sales, profitability, the adoption of its technology and products and FDA clearances are based on current expectations and beliefs and are subject to numerous risks and uncertainties, many of which are outside the company's control, that could cause actual results to differ materially. Factors that could affect the accuracy of these forward-looking statements include, but are not limited to: any inability by the company to sustain profitable operations or obtain additional financing on favorable terms if and when needed; any failure to obtain required regulatory approvals; failure of the medical community to expand its acceptance of TMR or PMC procedures; possible adverse governmental rulings or regulations, including any FDA regulations or rulings; the company's ability to comply with international and domestic regulatory requirements; possible adverse Medicare or other third-party reimbursement policies or adverse changes in those policies; any inability by the company to ship product on a timely basis; the company's ability to manage its growth; adverse economic developments that could adversely affect the market for our products or our ability to raise needed financing; actions by our competitors; restrictions contained in our convertible debt obligations requiring the issuance of shares rather than repayment in cash; and the company's ability to protect its intellectual property. Other factors that could cause Cardiogenesis' actual results to differ materially are discussed in the "Risk Factors" section of the company's Annual Report on Form 10-KSB for the year ended December 31, 2008 and the company's other recent SEC filings. The company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

    Cardiogenesis Corporation, +1-949-420-1800
   http://www.cardiogenesis.com


'/>"/>
SOURCE Cardiogenesis Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)...  Montoya Love is recognized by Continental Who,s Who ... Montoya is the Regulatory Systems Operations Manager with ... Manufacturing and selling a broad range of ... healthcare institutions, clinical laboratories and life science researchers with ... globe. ...
(Date:2/4/2016)... 2016  Omnicell, Inc. (NASDAQ: OMCL ), a leading ... systems, today announced results for its fiscal year and ... --> GAAP results: Revenue for the ... million or 4.1% from the third quarter of 2015, ... quarter of 2014. Revenue for the year ended December 31, ...
(Date:2/4/2016)... , Feb. 4, 2016  AMRI (NASDAQ:  AMRI) today ... of Pfizer Inc. and President of Pfizer Global Supply, has ... of February 4, 2016. In addition, the Company announced that ... the audit committee since 2010, has retired from the AMRI ... attention to his other business ventures.  William ...
Breaking Medicine Technology:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Love is ... roses in a variety of colors, assortments and packaging. This staple for Valentine’s Day ... King Kullen location. , For Valentine’s Day, not only are long-stem roses available, ...
(Date:2/5/2016)... Falls, NY & Salt Lake City, UT (PRWEB) , ... February ... ... Davis, Founder of Activz Whole-Food Nutrition , announced that the much-anticipated feature with ... on the New Really Cool Humans Amateur TV Network. , Each week, on his ...
(Date:2/5/2016)... ... ... The event is being held on April 7, 2016 from 5:30 p.m. to ... will fund nearly $100,000 for research for the care and cure of Parkinson’s disease. ... the architect of this informative event to raise awareness and funds for Parkinson’s. ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco ... micro-needling services in their Napa Valley office. The technique utilizes the body’s own ... Dr. Canales and Dr. Furnas, are part of only a select few cosmetic ...
(Date:2/5/2016)... Dickson, Tennessee (PRWEB) , ... February 05, 2016 ... ... State Community College President George H. Van Allen have signed a joint enrollment ... semester, provides a seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. ...
Breaking Medicine News(10 mins):